The global critical limb ischemia treatment market is experiencing strong momentum as the prevalence of peripheral arterial disease (PAD), diabetes, and cardiovascular disorders rises globally. CLI, the most severe form of PAD, is associated with chronic ischemic rest pain, tissue loss, ulcers, and gangrene, often leading to limb amputation if untreated. With advancements in endovascular interventions, regenerative medicine, and surgical techniques, the market is projected to expand substantially in the coming years.
According to Kings Research, the global critical limb ischemia treatment market size was valued at USD 4,635.3 million in 2024 and is projected to grow from USD 4,951.9 million in 2025 to USD 7,988.1 million by 2032, exhibiting a CAGR of 7.00% during the forecast period.
Critical Limb Ischemia Treatment Market: Key Highlights
-
CLI is a severe, life-threatening condition affecting millions globally, with high rates of amputation and mortality if left untreated.
-
Endovascular therapies such as angioplasty, stenting, atherectomy, and drug-coated balloons are revolutionizing the treatment landscape.
-
Regenerative therapies, including stem cell therapy and gene therapy, are emerging as promising approaches for promoting angiogenesis and limb salvage.
-
Hospitals and specialized vascular centers are the primary end-users, supported by growing healthcare investments and reimbursement frameworks.
-
North America leads the global CLI treatment market, followed by Europe, while Asia-Pacific is poised for the fastest growth due to rising awareness, improving healthcare infrastructure, and a high diabetic population base.
Comments
0 comment